Immatics pivotal position in the rapidly evolving cancer immunotherapy field is supported by a group of leading investors. So far the company has raised over €142m in equity capital and over €24m in non-dilutive funding. Through this funding and the continual development of the world-leading target discovery engine XPRESIDENT®, immatics is now uniquely positioned to take advantage of all high-potential opportunities in cancer immunotherapy.